Article thumbnail

Doxycycline for Malaria Chemoprophylaxis and Treatment: Report from the CDC Expert Meeting on Malaria Chemoprophylaxis

By Kathrine R. Tan, Alan J. Magill, Monica E. Parise and Paul M. Arguin

Abstract

Doxycycline, a synthetically derived tetracycline, is a partially efficacious causal prophylactic (liver stage of Plasmodium) drug and a slow acting blood schizontocidal agent highly effective for the prevention of malaria. When used in conjunction with a fast acting schizontocidal agent, it is also highly effective for malaria treatment. Doxycycline is especially useful as a prophylaxis in areas with chloroquine and multidrug-resistant Plasmodium falciparum malaria. Although not recommended for pregnant women and children < 8 years of age, severe adverse events are rarely reported for doxycycline. This report examines the evidence behind current recommendations for the use of doxycycline for malaria and summarizes the available literature on its safety and tolerability

Topics: Meeting Report
Publisher: The American Society of Tropical Medicine and Hygiene
OAI identifier: oai:pubmedcentral.nih.gov:3062442
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (1990). A comparative study of gastrointestinal infections in United States soldiers receiving doxycycline or mefloquine for malaria prophylaxis .
  2. (1988). A double-blind, multiple-dose, placebo-controlled, cross-over study to compare the incidence of gastrointestinal complaints in healthy subjects given Doryx R and Vibramycin R .
  3. (1985). Absorption of minocycline hydrochloride and tetracycline hydrochloride. Effect of food, milk, and iron .
  4. (1993). Activity of doxycycline against preerythrocytic malaria .
  5. (2000). Adverse effects of minocycline versus doxycycline in the treatment of Lyme neuroborreliosis .
  6. (2010). Alternatives for malaria prophylaxis during the first trimester of pregnancy: our personal view .
  7. (2006). American Academy of Pediatrics ,
  8. (2006). Antibiotic use in pregnancy and lactation .
  9. (2000). Antibiotics for prophylaxis of Plasmodium falciparum infections: in vitro activity of doxycycline against Senegalese isolates .
  10. (1971). Antimalarial effects of tetracyclines in man .
  11. (1999). Antimalarial prophylaxis–use and adverse events in visitors to the Kruger National Park .
  12. (1998). Antimicrobial photosensitive reactions .
  13. (1997). Assessment of the pharmacodynamic properties of antimalarial drugs in vivo .
  14. (2007). Association between tetracycline or doxycycline and hepatotoxicity: a population based case-control study .
  15. (2001). Bleeding associated with doxycycline and warfarin treatment.
  16. (2008). Case-control study of antibiotic use and subsequent Clostridium difficile-associated diarrhea in hospitalized patients . Infect Control Hosp Epidemiol 29: 44
  17. (2008). CDC Health Infor mation for International Travel
  18. (1949). Chloroquine, proguanil, mepacrine and quinine in the treatment of malaria caused by Plasmodium falciparum .
  19. (2001). Chloroquine/doxycycline combination versus chloroquine alone, and doxycycline alone for the treatment of Plasmodium falciparum and Plasmodium vivax malaria in northeastern Irian Jaya,
  20. (1999). Chronic intoxication by doxycycline use for more than 12 years .
  21. (1996). Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand .
  22. (1995). Clostridium difficile-associated diarrhoea after doxycycline malaria prophylaxis .
  23. (1968). Comparative concentrations of a tetracycline antibiotic in serum and maternal milk .
  24. (2006). Cost considerations of malaria chemoprophylaxis including use of primaquine for primary or terminal chemoprophylaxis .
  25. (1995). Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil .
  26. (1994). Differences in phototoxic potency should be considered when tetracyclines are prescribed during summer-time. A study on doxycycline and lymecycline in human volunteers, using an objective method for recording erythema .
  27. (1963). Discoloration of teeth induced by tetracycline administered ante partum .
  28. (1998). Doxycycline and staining of permanent teeth .
  29. (1995). Doxycycline for malaria prophylaxis in Australian soldiers deployed to United Nations missions
  30. (1981). Doxycycline in the treatment of falciparum malaria among aborigine children in West Malaysia .
  31. (1974). Doxycycline pharmacokinetics in the absence of renal function .
  32. (1987). Doxycycline prophylaxis for falciparum malaria .
  33. (2000). Doxycycline use for rickettsial disease in pediatric patients .
  34. (1997). Doxycycline vs. mefloquine . Mil Med 162: viii .
  35. (2002). Drug effects on the fetus and breast-fed infant .
  36. (2001). Drug interactions between oral contraceptives and antibiotics .
  37. (1996). Drug photosensitivity, idiopathic photodermatoses, and sunscreens .
  38. (1981). Drug therapy for Plasmodium falciparum malaria resistant to pyrimethamine-sulfadoxine (Fansidar). 529 DOXYCYCLINE AS AN ANTIMALARIAL A study of alternate regimens in Eastern Thailand,
  39. (1980). Drug therapy in renal failure: dosing guidelines for adults. Part I: antimicrobial agents, analgesics .
  40. (2003). Drug-induced hepatitis with autoimmune features during minocycline therapy .
  41. (2000). Drug-induced oesophageal disorders: pathogenesis, incidence, prevention and management .
  42. (1970). Effect of administration of tetracycline in pregnancy on the primary dentition of the offspring .
  43. (1975). Effect of antiepileptic drugs on the elimination of various tetracycline derivatives .
  44. (1995). Effectiveness of doxycycline combined with primaquine for malaria prophylaxis .
  45. (2008). Effects of different antimalarial drugs on gametocyte carriage in P. vivax malaria .
  46. (1974). Effects of lengterm treatment with tetracycline .
  47. (1972). Effects of minocycline against chloroquine-resistant falciparum malaria .
  48. (1975). Effects of minocycline and tetracycline on the vaginal yeast flora .
  49. (1971). Effects of tetracycline against chloroquineresistant and cloroquine-sensitive Plasmodium falcuparum .
  50. (1999). Efficacy of daily antimalarial chemoprophylaxis in tropical Africa using either doxycycline or chloroquine-proguanil; a study conducted in
  51. (1985). Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis .
  52. (1994). Failure of doxycycline as a causal prophylactic agent against Plasmodium falciparum malaria in healthy nonimmune volunteers .
  53. (1963). Fatal liver disease after intravenous administration of tetracycline in high dosage .
  54. (1965). Fatty liver of pregnancy and its relationship to tetracycline therapy .
  55. (1963). Growth inhibition of prematures receiving tetracycline .
  56. (2008). In vitro monitoring of Plasmodium falciparum drug resistance in French Guiana: a synopsis of continuous assessment from
  57. (1981). Inactivation of digoxin by the gut flora: reversal by antibiotic therapy .
  58. (1989). Induction of esophageal injuries by doxycycline and other pills. A frequent but preventable occurrence .
  59. (1989). Influence of milk on the bioavailability of doxycycline–new aspects .
  60. (1989). Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycyline, and amoxicillinclavulanic acid .
  61. (1995). Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro .
  62. (2007). Intracranial pressure returns to normal about a month after stopping tetracycline antibiotics .
  63. localization and nature of staining in extracted deciduous teeth .
  64. (1988). Long-term tetracycline use in the treatment of acne vulgaris–the role of routine laboratory monitoring .
  65. (1996). Malaria among United States troops in Somalia .
  66. (1992). Malaria chemoprophylaxis using proguanil/dapsone combinations on the Thai-Cambodian border .
  67. (1999). Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia . Clin Infect Dis 28: 74
  68. (1989). Malaria prophylaxis with doxycycline in soldiers deployed to the Thai-Kampuchean border .
  69. (1999). Malaria protection measures used by in-flight travelers to South African game parks .
  70. (2007). Malarone antimalarial agent. I n c .
  71. (2005). Medication-induced intracranial hypertension in dermatology .
  72. (1997). Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double-blind, placebo-controlled trial .
  73. (1993). Mefloquine or doxycycline prophylaxis
  74. (1996). Mefloquine versus doxycycline for malaria prophylaxis in intermittent exposure of Israeli Air Force aircrew in Rwanda .
  75. (1970). Methoxyflurane, tetracycline, and renal failure.
  76. (1972). Minocycline and tetracycline treatment of acute falciparum malaria in Thailand .
  77. (2000). Minocycline as a cause of drug-induced autoimmune hepatitis. Report of four cases and comparison with autoimmune hepatitis .
  78. (2001). Minocycline as a therapeutic option in bullous pemphigoid .
  79. (1996). Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome.
  80. (1998). Minocycline-induced cutaneous pigmentation .
  81. (2000). Minocycline-induced hyperpigmentation in patients with pemphigus and pemphigoid .
  82. (1996). Minocycline-induced liver injury .
  83. (1998). Minocycline-induced scleral, dental, and dermal pigmentation .
  84. (1998). Minocycline-related autoimmune hepatitis: case series and literature review .
  85. (2000). Minocyclineinduced generalized postinflammatory elastolysis .
  86. (1981). More on esophageal ulcerations due to tetracycline and doxycycline therapy .
  87. (2009). Multinormal in vitro distribu tion model suitable for the distribution of Plasmodium falciparum chemosusceptibility to doxycycline .
  88. (2007). Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast .
  89. (1995). National surveillance for Rocky Mountain spotted fever, 1981–1992: epidemiologic summary and evaluation of risk factors for fatal outcome .
  90. (1998). Oral and systemic effects of prolonged minocycline therapy .
  91. (2002). Oral contraceptive efficacy and antibiotic interaction: a myth debunked .
  92. (1997). Oral contraceptive failure rates and oral antibiotics.
  93. (1993). Phototoxic eruptions due to doxycycline–a dose-related phenomenon .
  94. (2008). Physicians’ Desk Reference .
  95. (1991). Plasma quinine levels in patients with falciparum malaria when given alone or in combination with tetracycline with or without primaquine .
  96. (1997). Potentiation of the antimalarial activity of atovaquone by doxycycline against Plasmodium falciparum in vitro .
  97. (2009). Predicting drug-drug interactions: and FDA perspective .
  98. (2006). Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I .
  99. (2002). Product Information: vibramycin brand of doxycycline monohydrate .
  100. (1988). Prophylactic treatment of vivax and falciparum malaria with low-dose doxycycline .
  101. (1992). Quinine with tetracycline for the treatment of drug-resistant falciparum malaria in Thailand .
  102. (1994). Randomized trial of mefloquine-tetracycline and quinine-tetracycline for acute uncomplicated falciparum malaria .
  103. (1993). Recent military experience with malaria chemoprophylaxis .
  104. (2010). Reliability of antimalarial sensitivity tests depends on drug mechanisms of action .
  105. (1998). Rocky Mountain spotted fever .
  106. (2005). Safety of doxycycline and minocycline: a systematic review .
  107. (1996). Safety of long-term highdose minocycline in the treatment of acne .
  108. (1976). Safety of long-term tetracycline therapy for acne .
  109. (1991). Second-generation tetracyclines, a dermatologic overview: clinical uses and pharmacology .
  110. (2007). Self-reported adverse events associated with antimalarial chemoprophylaxis in Peace Corps volunteers .
  111. (2009). Sex affects the steady-state pharmacokinetics of primaquine but not doxycycline in healthy subjects .
  112. (1990). Should tetracycline be contraindicated for therapy of presumed Rocky Mountain spotted fever in children less than 9 years of age?
  113. (1952). Studies on antibiotic synergism and antagonism: a scheme of combined antibiotic action .
  114. (1998). Successful double-blinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in western Kenya .
  115. (2006). Successful treatment of Plasmodium falciparum malaria with a six-doxe regimen of artemether-lumefantrine versus quinine-doxycycline in the Western Amazon regioni of Brazil .
  116. (2010). Susceptibility of Plasmodium falciparum isolates to doxycycline is associated with pftetQ sequence polymorphisms and pftetQ and pfmdt copy numbers .
  117. (1998). Systemic antibiotics for acne .
  118. (1962). Teeth pigmented by tetracycline .
  119. (1997). Teratogenic study of doxycycline .
  120. (1981). Tetracycline and benign intracranial hypertension: report of five cases .
  121. (1991). Tetracycline for Rocky Mountain spotted fever .
  122. (1977). Tetracycline therapy for acne: incidence of vaginitis .
  123. (1972). Tetracycline treatment of chloroquine-resistant falciparum malaria
  124. (1981). Tetracycline-associated fatty liver of pregnancy, including possible pregnancy risk after chronic dermatologic use of tetracycline .
  125. (1972). Tetracycline, methoxyflurane anaesthesia, and renal dysfunction.
  126. (1971). Tetracyclines and permanent teeth: the relation between dose and tooth color .
  127. (2006). Tetracyclines specifically target the apicoplast of the malaria parasite P. falciparum .
  128. (1991). The effect of doxycycline on serum levels of ethinyl estradiol, norethindrone, and endogenous progesterone .
  129. (1964). The effect of tetracycline on mineralization and growth .
  130. (1983). The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man .
  131. (1970). The incidence of staining of permanent teeth by the tetracyclines .
  132. (1997). The sensitivity of Plasmodium protein synthesis to prokaryotic ribosomal inhibitors .
  133. (1982). The tetracyclines .
  134. (2009). The Uncommon Drugstore . Available at : www.drugstore.com .
  135. (2002). Tolerability of doxycycline monohydrate salt vs. chloroquine-proquanil in malaria chemoprophylaxis . Trop Med Int Health 7: 919
  136. (2007). Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicenter, randomized, double blind, four arm study .
  137. (1992). Tooth discoloration resulting from long-term tetracycline therapy: a case report .
  138. (2001). Transfer of drugs and other chemicals into human milk .
  139. (1974). Treatment of drug-resistant malaria in man .
  140. (2001). Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine .
  141. (2007). Treatment of malaria in the United States: a systematic review .
  142. (2007). Treatment of uncomplicated Plasmodium falciparum malaria with quinine-doxycycline combination therapy .
  143. (2001). Update: interim recommendations for antimicrobial prophylaxis for children and breastfeeding mothers and treatment of children with anthrax .
  144. (1981). Urinary excretion of reduced metabolites of digoxin .
  145. (1964). Vaginal moniliasis after tetracycline therapy: the effects of amphotericin
  146. (2007). Vibramycin [package insert] .
  147. (2006). Vivotif [package insert] . Switzerland : Berna Biotech Ltd .